Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neuren Pharmaceuticals’ (NEU) U.S. partner ACADIA has lifted the temporary enrolment pause for the phase three trial of its trofinetide drug
  • The LAVENDER trial is testing the therapy in woman and girls with Rett Syndrome, a neurodevelopmental disorder arising from a rare gene mutation
  • Enrolment in LAVENDER, and its 40-week LILAC extension study, will now continue where possible across the U.S.
  • Neuren is also pursuing trials of trofinetide and its novel NNZ-2591 drug in other neurodevelopmental syndromes
  • Neuren Pharmaceuticals is trading 4.7 per cent higher today, at $1.57 per share

Drug developer Neuren Pharmaceuticals’ (NEU) U.S. partner ACADIA has lifted the temporary enrolment pause for the phase three trial of its trofinetide drug.

The LAVENDER trial is testing the therapy in woman and girls with Rett Syndrome, a neurodevelopmental disorder arising from a rare gene mutation.

Virus hiatus

The LAVENDER study was underway before the onset of the COVID-19 pandemic, but had not enrolled the full study cohort.

ACADIA was forced to suspend enrolment in the trofinetide Rett Syndrome study, due to risks associated with clinic visitation and lack of medical resources during the pandemic.

The study is seeking to evaluate the efficacy and safety of trofinetide against a placebo in around 180 girls and young women aged between five and 20 years.

There are still certain difficulties associated with the trial, including site availability and local health guidelines, which may affect enrolments. ACADIA assures any potential enrolees it will be “taking appropriate measures to safely and effectively collect patient data to ensure the integrity of study results.”

Next steps

Enrolment in LAVENDER, and its 40-week LILAC extension study, will now continue where possible across the U.S.

Neuren and ACADIA will also continue the phase two trial of trofinetide in Fragile X syndrome.

Neuren is also undertaking trials of its novel NNZ-2591 drug for Phelan-McDermid, Angelman and Pitt Hopkins syndromes, each of which has received orphan drug designation in the United States.

Neuren Pharmaceuticals is trading 4.7 per cent higher today, at $1.57 per share as at 12:05 pm AEST.

NEU by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.